Segment and Geographic Information (Tables)

12 Months Ended

Dec. 31, 2016

Schedule of Segment Reporting Information, by Segment



	Year Ended December 31, 2016
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales to external customers	$	154,249	$	497,137	$	207,768	$	—		$	859,154
Depreciation and amortization expense	9,984		18,432		5,953		3,140			37,509
Operating income (loss) ⁽¹⁾⁽²⁾	13,307		50,435		41,967		(48,337		)	57,372
Total assets⁽³⁾	177,514		657,599		178,747		219,222			1,233,082
Capital expenditures	3,316		11,706		2,303		460			17,785



	Year Ended December 31, 2015
	Energy & Chemicals			Distribution & Storage		BioMedical			Corporate			Total
Sales to external customers	$	330,968		$	487,557	$	221,635		$	—		$	1,040,160
Depreciation and amortization expense	11,805			18,289		12,039			3,315			45,448
Operating (loss) income ⁽²⁾⁽⁴⁾	(10,050		)	39,549		(165,336		)	(47,386		)	(183,223		)
Total assets ⁽³⁾	251,810			689,112		224,443			34,775			1,200,140
Capital expenditures	4,074			36,835		3,849			2,281			47,039



	Year Ended December 31, 2014
	Energy & Chemicals		Distribution & Storage		BioMedical		Corporate			Total
Sales to external customers	$	388,018	$	578,806	$	226,128	$	—		$	1,192,952
Depreciation and amortization expense	9,649		16,749		13,842		2,936			43,176
Operating income (loss) ⁽²⁾⁽⁵⁾	78,006		82,612		25,009		(47,470		)	138,157
Total assets ⁽³⁾	322,936		666,451		396,320		73,810			1,459,517
Capital expenditures	24,834		29,583		3,484		4,234			62,135

_______________

⁽¹⁾

During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $376, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1,217 attributed to D&S.

⁽²⁾

Beginning in 2016, the Company allocates share-based compensation expense to each operating segment and maintains share-based compensation expense related to Corporate employees at Corporate. Prior to 2016, all share-based compensation expense was recorded at Corporate. Reclassifications from Corporate to the operating segments have been made to the 2015 and 2014 SG&A to conform to the 2016 presentation.


⁽³⁾	Corporate assets consist primarily of cash, cash equivalents, and deferred income taxes.


⁽⁴⁾	Includes asset impairment charges of $255,116 for the year ended December 31, 2015, attributed to E&C - $68,796, D&S - $2,020, and BioMedical - $184,300.


⁽⁵⁾	The BioMedical segment’s operating income included recovery of $5,003 increasing operating income for the year ended December 31, 2014 from an escrow settlement for breaches of representations and warranties relating to warranty costs (which are in excess of the settlement amount) for certain product lines acquired from AirSep in 2012.

Schedule of Goodwill [Table Text Block]

The following table presents the changes in goodwill:



	December 31,
	2016			2015
Beginning balance	$	218,390		$	405,522
Foreign currency translation adjustments and other	(420		)	(1,887		)
Goodwill acquired during the year	—			10,601
Impairment loss	—			(195,846		)
Ending balance	$	217,970		$	218,390

Accumulated goodwill impairment loss	$	195,846		$	195,846

The following table represents the changes in goodwill by segment:



	Energy & Chemicals			Distribution & Storage			BioMedical			Total
Balance at January 1, 2015	$	92,638		$	157,248		$	155,636		$	405,522
Foreign currency translation adjustments and other	(162		)	(1,909		)	184			(1,887		)
Goodwill acquired during the year	—			10,601			—			10,601
Impairment loss	(64,603		)	—			(131,243		)	(195,846		)
Balance at December 31, 2015	27,873			165,940			24,577			218,390
Foreign currency translation adjustments and other	—			(420		)	—			(420		)
Balance at December 31, 2016	$	27,873		$	165,520		$	24,577		$	217,970

Accumulated goodwill impairment loss	$	64,603		$	—		$	131,243		$	195,846

Revenue from External Customers by Products and Services [Table Text Block]



	Year Ended December 31,
	2016		2015		2014
Energy & Chemicals
Natural gas processing (including petrochemical) applications	$	105,372	$	180,909	$	208,706
Liquefied natural gas applications	38,184		136,049		143,870
Industrial gas applications	10,693		14,010		35,442
Total Energy & Chemicals	154,249		330,968		388,018
Distribution & Storage
Bulk industrial gas applications	227,650		203,834		204,214
Packaged gas industrial applications	159,681		167,814		164,966
Liquefied natural gas applications	109,806		115,909		209,626
Total Distribution & Storage	497,137		487,557		578,806
BioMedical
Respiratory therapy	118,926		132,321		141,273
Life sciences	70,572		64,641		65,948
Commercial oxygen generation	18,270		24,673		18,907
Total BioMedical	207,768		221,635		226,128
Total	$	859,154	$	1,040,160	$	1,192,952

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

Net sales by geographic area are reported by the destination of sales. Net property, plant and equipment by geographic area are reported by country of domicile.



	Sales for the Year Ended December 31,
	2016		2015		2014
United States	$	425,985	$	513,691	$	560,846
Foreign
China	147,720		109,978		188,047
Other foreign countries	285,449		416,491		444,059
Total Foreign	433,169		526,469		632,106
Total	$	859,154	$	1,040,160	$	1,192,952



	Property, plant and equipment, net as of December 31,
	2016		2015
United States	$	145,014	$	153,987
Foreign
Czech Republic	18,454		19,742
China	75,409		79,691
Germany	11,572		12,246
Other foreign countries	600		611
Total Foreign	106,035		112,290
Total	$	251,049	$	266,277